ASP Isotopes (NASDAQ: ASPI) closed the first quarter of 2026 as a materially different company than the one that filed its annual report for fiscal 2025 two months earlier, and the share price has already moved to reflect that. The January 6 acquisition of South African onshore gas-and-helium developer Renergen, the March 29 deconsolidation of construction-services unit Skyline, and the August 6 announcement of a fresh five-year take-or-pay LNG contract together reset the operating profile. First-quarter revenue was $4.2 million, up 279% year over year from $1.1 million as the radiopharmacy and now-LNG product lines together replaced a quarter that was still essentially pre-revenue; the GAAP net loss narrowed to $7.1 million from $8.5 million a year ago only because a $19.6 million gain on the Skyline deconsolidation offset a $24.9 million operating loss. After the closing price of $4.28 on August 13, the market capitalisation is $539 million, the trailing P/S is roughly 16x on a Q1 base (1.6x annualised at the Q1 run-rate, with that annualisation still speculative given first-shipment timing), and the 52-week range of $3.54–$14.05 captures the entire Renergen-deal-and-delays cycle.
The single most consequential near-term event is the planned listing of Renergen under a new ticker, NOBA, through a reverse merger with ENDRA Life Sciences, with a private placement of approximately $50 million, ASPI retaining roughly 89% of the new entity. That step is a real, dated operational milestone with regulatory and shareholder-vote gating, not a non-binding optionality. The second is the planned public listing of QLE, the nuclear-fuels subsidiary, with a $300 million-plus 2031 EBITDA target. Both are what management has called its "sum-of-the-parts" strategy. The investment case at $4.28 is whether the market will re-rate each subsidiary independently at multiples higher than the consolidated parent, or whether the delays in stable-isotope production and the increased quarterly operating cash use keep the parent pinned until a real revenue inflection.